trending Market Intelligence /marketintelligence/en/news-insights/trending/zW40fiwljf0ar5qrtJclcQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Japan approves Gilead's hepatitis B treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Japan approves Gilead's hepatitis B treatment

Japan's Ministry of Health, Labour and Welfare approved Gilead Sciences Inc.'s Vemlidy 25 mg for patients with chronic hepatitis B.

"There are currently more than one million people in Japan chronically infected with hepatitis B, and we believe Vemlidy is an important option for patients living with this disease," Gilead Chief Scientific Officer and Executive Vice President of Research and Development, Norbert Bischofberger, said in a statement.

The Gilead drug will compete with GlaxoSmithkline Pharmaceuticals Ltd.'s tenofovir disoproxil fumarate in Japan.